M. D. C. Barrigón

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

A. Hagenbeek, J. Radford, K. Ardeshna, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).

M. Kersten, N. Schmitz, P. Riedell, 2018 .

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

A. López-Guillermo, A. Nagler, B. K. Masouleh, 2017 .

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

A. Hagenbeek, J. Radford, K. Ardeshna, 2014 .

Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype.

J. S. San Miguel, M. D. del Carmen, R. García-Sanz, 1998, Haematologica.

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

A. Hagenbeek, J. Radford, K. Ardeshna, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.